Dr. Singh is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Ave
Boston, MA 02215Phone+1 617-582-7956
Summary
- Prabhsimranjot Singh, MD, is an oncologist based in Boston, MA, who serves as a Senior Physician at the Dana-Farber Cancer Institute. He completed his fellowship and residency in Hematology and Medical Oncology and Internal Medicine, respectively, at Maimonides Medical Center, following his graduation from Indira Gandhi Medical College in 2009. His expertise encompasses head and neck oncology, melanoma and cutaneous malignancies, myeloproliferative disease, gastrointestinal oncology, and thoracic oncology. Dr. Singh has an impressive list of research publications, some of which have been cited numerous times, and is involved in several clinical trials primarily focusing on improving treatments for rectal and non-small cell lung cancers.
Education & Training
- Maimonides Medical CenterFellowship, Hematology and Medical Oncology, 2014 - 2017
- Maimonides Medical CenterResidency, Internal Medicine, 2011 - 2014
- Indira Gandhi Medical CollegeClass of 2009
Certifications & Licensure
- MA State Medical License 2017 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation Start of enrollment: 2022 Dec 08
- Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease Start of enrollment: 2022 Mar 10
- Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial Start of enrollment: 2020 Jun 16
Publications & Presentations
PubMed
- 2 citationsEnhancing Precision in Detecting Severe Immune-Related Adverse Events: Comparative Analysis of Large Language Models and International Classification of Disease Codes ...Virginia H Sun, Julius C Heemelaar, Ibrahim Hadzic, Vineet K Raghu, Chia-Yun Wu
Journal of Clinical Oncology. 2024-12-10 - 1 citationsComplementary and Alternative Medicine Use in Patients With Cancer and Immigration Background.Alex Wu, Yunhong Wu, Vijaya Natarajan, Prabhsimranjot Singh, Waseem Cheema
JCO Global Oncology. 2023-06-01 - 7 citationsNovel platform leveraging electronic medical record (EMR) to triage patients admitted with high-grade immune-related adverse events (irAEs) to the immune-toxicity (ITO...Osama Abu-Shawer, Prabhsimranjot Singh, Eric Yenulevich, Amanda Brito, Jian Ni
Journal for Immunotherapy of Cancer. 2020-08-01
Committees
- Cancer Liason Phsyician, Commission on Cancer 2020 - 2023
Professional Memberships
- Member
- Member
- Member
Other Languages
- Hindi, Punjabi
External Links
- DFCI https://www.dana-farber.org/find-a-doctor/prabhsimranjot-singh
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: